News

Zacks.com on MSN5h
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults
FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.
Fierce Pharma5h
Regulatory tracker: FDA accepts GSK expansion filing for RSV vaccine Arexvy
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...
Medscape8h
ACG Refreshes Preventive Care in IBD Guidance
The update covers the safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, skin cancer ...
KFF Health News6h
Arizonan Dies Of Pneumonic Plague
The diagnosis was confirmed through rapid testing after the Coconino County resident was admitted to Flagstaff Medical Center. Pneumonic plague is the only form of the plague that can be transmitted ...
GSK seeks FDA nod for expanded use of RSV vaccine in adults
British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...
Pharmaceutical Technology on MSN7h
GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients
The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...
European trade ministers pledge unity after Trump’s surprise 30% tariffs
European trade ministers were hopeful for a negotiated trade deal after Trump announced 30% tariffs on the European Union.